CTNM vs IMVT
CTNM: Contineum Therapeutics is a clinical-stage biotech developing small molecule therapies for neuroscience, inflammation, and immunology. IMVT: Immunovant is a clinical-stage biotechnology company developing FcRn-inhibiting therapies to treat patients suffering from debilitating IgG-mediated autoimmune diseases.
Side-by-side fundamentals
| Metric | CTNM | IMVT | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $14.49 | $39.89 | |
| Market cap as of 2026-08-11 | $335M | $8.2B | |
| Net margin as of 2026-08-11 | +45.4% | n/a | |
| Operating margin as of 2026-08-11 | +32.1% | n/a | |
| ROE as of 2026-08-11 | -27.1% | -69.6% | CTNM higher |
| ROA as of 2026-08-11 | -25.6% | -62.5% | CTNM higher |
| Debt / equity as of 2026-08-11 | 0.00 | 0.00 | Tie |
| Beta as of 2026-08-11 | 0.34 | 0.81 | |
| 1-year return as of 2026-08-10 close | +124.0% | +158.0% | IMVT higher |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.